Ionis Pharmaceuticals, Inc. (IONS) Reaches $78.54 52-Week High; Shorts at MERLIN ENTERTAINMENTS PLC ORDINARY SHARE (MIINF) Raised By 2.4%

Merlin Entertainments plc (OTCMKTS:MIINF) Logo

MERLIN ENTERTAINMENTS PLC ORDINARY SHARE (OTCMKTS:MIINF) had an increase of 2.4% in short interest. MIINF’s SI was 1.99 million shares in March as released by FINRA. Its up 2.4% from 1.94 million shares previously. It closed at $4.54 lastly. It is down 0.00% since March 17, 2018 and is . It has underperformed by 4.37% the S&P500.

The stock of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) hit a new 52-week high and has $81.68 target or 4.00% above today’s $78.54 share price. The 5 months bullish chart indicates low risk for the $10.87 billion company. The 1-year high was reported on Mar, 17 by Barchart.com. If the $81.68 price target is reached, the company will be worth $434.80M more. The stock increased 1.42% or $1.1 during the last trading session, reaching $78.54. About 977,167 shares traded. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has risen 33.45% since March 17, 2018 and is uptrending. It has outperformed by 29.08% the S&P500. Some Historical IONS News: 17/04/2018 – Ionis Licenses Akcea Worldwide Rights to Inotersen and AKCEA-TTR-L; 18/05/2018 – STAT Plus: ‘Standing on the shoulders of Spinraza,’ a startup seeks answers to insidious form of epilepsy; 15/03/2018 – AKCEA THERAPEUTICS – CO, IONIS ARE ALSO DEVELOPING AKCEA-TTR-L(RX) FOR HEREDITARY AND WILD-TYPE FORMS OF ATTR; 04/05/2018 – IONIS PHARMA 1Q CASH & OTHER $1.04B; 09/04/2018 – IONIS & ASTRAZENECA ADVANCE NEW DRUG FOR NASH; 21/03/2018 – MHRA Grants UK Patients Early Access to Akcea Therapeutics’ Volanesorsen for Familial Chylomicronaemia Syndrome (FCS); 24/04/2018 – Ionis Pharmaceuticals to Hold First Quarter 2018 Financial Results Webcast; 19/04/2018 – PREVIEW NEUROLOGY: Alder, AveXis, Ionis Set for L.A. Meeting; 09/04/2018 – IONIS EARNS $30M LICENSE FEE FOR IONIS-AZ6-2.5-L RX; 20/04/2018 – BIOGEN – CO, IONIS EXPANDED COLLABORATION THROUGH NEW 10-YR AGREEMENT TO DEVELOP NOVEL ANTISENSE DRUG CANDIDATES FOR RANGE OF NEUROLOGICAL DISEASES

More notable recent Merlin Entertainments plc (OTCMKTS:MIINF) news were published by: Seekingalpha.com which released: “Harvest One Cannabis: Highly Undervalued Cannabis Stock – Seeking Alpha” on March 12, 2019, also Seekingalpha.com with their article: “Green Growth Brands: It Seems Very Expensive – Seeking Alpha” published on March 12, 2019, Seekingalpha.com published: “Vivo Cannabis: Very Undervalued – Seeking Alpha” on February 20, 2019. More interesting news about Merlin Entertainments plc (OTCMKTS:MIINF) were released by: Midasletter.com and their article: “Namaste Technologies Inc (CVE:N): Decision Time For Remaining Shareholders – Midas Letter” published on March 10, 2019 as well as Seekingalpha.com‘s news article titled: “Prosegur: Value Increases As Price Falls – Seeking Alpha” with publication date: March 10, 2019.

Merlin Entertainments plc operates visitor attraction places worldwide. The company has market cap of $4.82 billion. The firm operates midway attractions under the Madame Tussauds, The Eye Brand, SEA LIFE, The Dungeons, LEGOLAND Discovery Centres, Seal Sanctuaries, Blackpool Tower, WILD LIFE, Australian Treetop Adventures, Hotham Alpine Resort, Falls Creek, and Shreks Adventure London brands. It has a 17.07 P/E ratio. It also operates LEGOLAND parks under the LEGOLAND Billund, LEGOLAND Windsor, LEGOLAND California, LEGOLAND Deutschland, LEGOLAND Florida, LEGOLAND Malaysia, LEGOLAND Dubai, and LEGOLAND Japan brands; and resort theme parks under the Alton Towers, Chessington World of Adventures, Gardaland, Heide Park, THORPE PARK Resort, and Warwick Castle brand names.

More notable recent Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news were published by: Seekingalpha.com which released: “Ionis Pharmaceuticals Q4 Earnings Preview – Seeking Alpha” on February 26, 2019, also Nasdaq.com with their article: “Ionis Pharmaceuticals Funds Its Pipeline of More Than 40 Drugs – Nasdaq” published on March 04, 2019, Nasdaq.com published: “Akcea and Ionis Announce Upcoming Data Presentations at the 2019 American College of Cardiology Meeting (ACC.19) – Nasdaq” on March 15, 2019. More interesting news about Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) were released by: Nasdaq.com and their article: “5 Mid-Cap Stocks You Need To Know About Right Now – Nasdaq” published on March 06, 2019 as well as Nasdaq.com‘s news article titled: “Analysts Estimate Ionis Pharmaceuticals (IONS) to Report a Decline in Earnings: What to Look Out for – Nasdaq” with publication date: February 20, 2019.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics. The company has market cap of $10.87 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet. It has a 37.94 P/E ratio. The Company’s drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Ratings Chart